# JLABS @ BE

The European gateway to the global JLABS ecosystem

**SMB** meeting 21 November

**Tom Aelbrecht Senior Director Operations - JLABS EMEA** 





Innovation at Johnson & Johnson is about creating strong networks of people who can combine resources, ideas and technologies in a new way.

Paul Stoffels, MD Chief Scientific Officer

### JLABS:

## **Small** Companies **Get Big** Company **Benefits**

Infrastructure



**Programming** 



**Access to Expertise** 



**Visibility** 



**Funding Opportunities** 



**Global Network** 





### **Our Infrastructure**



**Wet Labs & Private Offices** 



**Operational Management** 



**Equipment & Storage** 



#### Resource Hub


Big company benefits for small companies



#### **Powered by JLABS Partners**

Support for small companies comes in many different forms. At Johnson & Johnson Innovation, JLABS we work with external partners to provide a strong community of resources for our residents. This network is strengthened by our internal procurement team who is leveraging the J&J network of external providers, to help deliver benefits that reduces costs, increases access and improves knowledge of the residents.

The Resource HUB serves as a key center to connect preferred providers to JLABS companies.



- Human Resources
- Lab Supplies
- Equipment
- IT Support
- Financial Services

- Web Services
- Compound Libraries
- Insurance
- Relocation Services
- And...

#### **JPALS**




Access to expertise, mentorship and connections to support your growth



# Powered by Johnson & Johnson experts

JLABS residents and alumni have access to a wealth of Johnson & Johnson internal expertise in pharmaceuticals, medical devices, consumer products and cross sector initiatives through the JPAL program. JPALS provide resident companies with a forum to explore potential areas of partnership within Johnson & Johnson, as well as mentorship, coaching and contacts to support their growth.

#### 230+ JPALS at 40 Locations



### Tapping into the 130,000+ Johnson & Johnson Employees



**Marketing** 



R&D



**Clinical Trials** 





**Market Access** 




Regulatory



Media





#### **Investor Hub**

Investors interested in joining the Investor Hub should contact us.



#### The Future – Powered by JJDC

With the commitment and backing of JJDC, Investor Hubs are launching across all JLABS locations. The power of JJDC is bringing along investors of all types and focuses – unlocking unlimited potential for JLABS portfolio companies. We started with one in Toronto and now have more than 30 investor groups across North America! JJDC will be a physical presence, fostering mentorship and investment for JLABS portfolio companies, bringing along an extensive network of syndicate investors.

JJDC is the strategic venture arm of Johnson & Johnson, they invest across all sectors and at all stages, from seed-level start-ups to Series B and beyond.






























































































































































本草资本 3E Bioventures



Fresco



北极光创投 northern light











THUJA CAPITAL

### **Programs**

Capacity building and connections for early stage companies



#### **JLABS Programs**

Programs at JLABS provide an experience beyond the bench for scientists and entrepreneurs. Our programs allow JLABS residents, alumni, and the innovation ecosystem to make connections and gain valuable insights through workshops, networking events, access to J&J experts, and more. Programs include:

- Funding Series
- Science First
- Educational Workshops
- Health Tech @ JLABS Programming

- Meet with...
- Networking Events
- Community Engagement
- Lunch & Learns













### When we say "No-Strings-Attached" we mean it.

113

collaborations with Johnson & Johnson & JLABS companies

\$22.8B

secured collectively, by **JLABS** companies through financing and strategic relationships

#### JLABS companies have done deals with...

- ORBIMED
- BRISTOL-MYERS **SQUIBB**
- PFIZER
- 5AM VENTURES
- SR ONE
- SOFINNOVA

- JJDC
- GOOGLE VENTURES
- CELGENE
- POLARIS VENTURES
- THIRD ROCK
- MERCK
- NOVARTIS

- AMGEN
- JNJ
- ABBVIE
- ATLAS VENTURES
- MRM
- ARCH VENTURES
- VERSANT VENTURES

- BAYER
- ILLUMINA
- DRAPER FISHER **JURVESTON**
- KLEINER PERKINS **CAUFIELD & BYERS**

public companies

JLABS companies

Are still in business/acquired

acquisitions

collaborations between

#### o o —

# We put your company in the spotlight





#### **Exposure**

#### Social promotion and engagement with JLABS companies for content





Congrats to OCTIMET Oncology NV for being awarded a €1.077 million R&D grant from @VLAIO\_be. bit.ly/2PbGf7A #JLABSBE #EFRO



9:29 AM - 16 Aug 2018



Breanne Halvk and 5 others liked JLABS @JLABS · 26 Oct 2018

Congratulations to #JLABSBE Resident Company @genomebiologics on securing €2.42 million from @EU H2020 for their project "Reducing the cost, time, and ethical burden of preclinical research in the pharmaceutical industry. Well done! #EFRO bit.ly/2Q2giHG



Tina McGrath and 1 other liked



JLABS @JLABS · 5 Dec 2018 European QuickFire Challenge winner, AlphaBiomics, is developing #microbiome based predictive diagnostic and companion therapeutic products to enable safer and more efficacious drug therapies - bit.ly/2Pmd7ZZ

#InsideScoop #JLABSBE #EFRO



#### MICROBIOME REGULATIONS FROM AN EU START-UP'S PERSPECTIVE

Written by ALB on Friday 9 November 2018 in the category Insights with the tags startup, microbiology, regulatory.



Interested in the microbiome? So are we! Here's a sneak-peek into S-Biomedic, one of the first microbiome start-ups in Belgium We asked her to tell us about the challenge of being a new company developing an innovative product in a field where the regulations haven't quite caught up with reality.

#### A worldly company

As is the case for many European companies, S-Biomedic is an incredibly international organization. The company was founded in Barcelona in 2014 by German scientist Bernhard

Pätzold, Czech manager Veronika Oudova and Spanish scientist Marc Güell. After a stint at a business

JLABS JLABS



#### Congratulations to JLABS @ BE resident company @syndesi\_tx!

Syndesi Therapeutics @syndesi\_tx

Very pleased to announce that our lead molecule in development for cognitive impaitment, SDI-118, has entered Phase I. . The study includes PET imaging to directly measure the binding of SDI-118 to SV2A in the brain, syndesitherapeutics.com/news

1:12 PM - 8 May 2019

















### **Explore the global JLABS portfolio**

600+

#### **Total companies** including alumni

**JLABS** NAVIGAT R

INTRODUCING THE NEW JLABS NAVIGATOR -An easy-to-use database highlighting the many innovations and solutions across the JLABS portfolio.

JLABS.BUZZ/NAVIGATOR




#### **JLABS** NAVIGAT9R

#### The entire JLABS portfolio at your finger tips

- Customized solution for you to search & find the JLABS companies that are working in your areas of interest
- Have all of the information at your fingertips to be able to connect with them.

https://jlabs.jnjinnovation.com/JLABSNavigator#/



Medical Devices | Vision Care | Opthamology

VisiPlate is a nanoscale drainage implant that

creates a new outflow pathway for pent-up fluid

in the eye. Excess intraocular fluid flows through

surrounding tissue overtime, alleviating pressure

competitors like the Ahmed Glaucoma Valve and

the Baerveldt Glaucoma Shunt, VisiPlate avoids

eve muscles in the eve posterior, where these

VisiPlate and is slowly absorbed into

on the optic nerve. 10.000x thinner than

competitors are implanted and often fail

Site Head

Solution

Show More

Rui Jing Jiang

Nicholas Pachuda 😑

### JLABS @ BE













































#### **Selection Criteria & Process**




**Submit Non-Confidential Company Information** 



Presented to Selection Committee



**Notification of Accept** or Reject



### Johnson & Johnson DOES NOT...



#### See confidential information




#### **Own any IP**



#### Have any first rights

# Diversity as a driver for innovation





- 28% JLABS companies across the world have a female lead – 52% in Europe
- 27% JLABS companies across the world are lead by under-represented ethnic minorities\*

\*alumni or current resident companies located on a JLABS site in North America

# Stay in touch!

Newsletter | jlabs.jnjinnovation.com/subscribe

**Events** | jlabs.jnjinnovation.com/events/eu

Twitter | @JLABS

Email | jlabsbe@its.jnj.com

